Updates: Lung
Overcoming optimisation hurdles of high-throughput FMT assay
Several hurdles faced by many scientists, when developing assays and models for drug discovery, were highlighted at the 2023 European Respiratory Society (ERS) Congress. Understanding and investigating…
Read update
An insight into R&D at Newcells Biotech with Dr Fiona Leslie, PhD, Lung platform scientist
Can you tell us a little bit about your professional journey and how you made the transition to industry? I have an undergraduate Degree in biomedical science and also completed…
Read update
3rd ILD Summit Highlights
About the conference : ILD Summit The ILD Summit is a niche industry dedicated conference focussed on advancing therapies for progressive fibrosing interstitial lung diseases (ILD). This year’s conference was the…
Read update
Pulmonary toxicity – a challenge for drug development
Despite the common assumption that adverse drug reactions usually affect the kidney and liver, over 600 medications have been reported to induce lung toxicity.1 Due to ehri large surface area,…
Read update
Antibody drug conjugates (ADCs) – the role of in vitro models in safety assessment
One the fastest growing approaches to treat cancer is the use of antibody drug conjugates (ADCs). Since the approval of the first antibody drug conjugate in 2000,…
Read update
The latest FMT Assay: An invaluable tool for modelling fibrotic disease
Fibrotic diseases, including liver fibrosis, pulmonary fibrosis, and renal fibrosis, are characterized by the excessive deposition of extracellular matrix (ECM) components, leading to the formation of fibrous tissue that…
Read update
